Sarah Bettigole, Ph.D.

Sarah is a talented researcher with a deep knowledge of immunology and drug development. Prior to joining Volastra, Sarah co-founded Quentis Therapeutics, a company focused on targeting ER stress response pathways for cancer treatment. During her tenure she was director of biology and research project lead. She graduated from Tufts University with a bachelor’s in biology and earned her Ph.D. in immunology from Harvard University.